Skip to main content
Top

2014 | OriginalPaper | Hoofdstuk

7. Farmaco-economie

Auteurs : Maarten Postma, Cornelis Boersma

Gepubliceerd in: Handboek farmaceutische geneeskunde

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Inleiding

Bij het beoordelen van nieuwe geneesmiddelen wordt doelmatigheid van steeds groter belang. Het College voor Zorgverzekeringen beoordeelt de doelmatigheid van geneesmiddelen. Maar wat mag een gewonnen levensjaar of gewonnen kwaliteit van leven eigenlijk kosten? Waar andere landen een drempelwaarde kennen, ontbreekt die in Nederland. Dit hoofdstuk gaat in op de diverse aspecten die samenhangen met deze onderwerpen. Het beoogt mogelijke antwoorden te geven op vragen als: wat is kosteneffectief; hoe doe je een goede farmaco-economische analyse; wat is gangbaar bij de rapportage van farmaco-economische studies; hoe verhoudt de farmaco-economie in Nederland zich tot ontwikkelingen elders in de wereld; wat zijn illustratieve voorbeelden?
Literatuur
go back to reference Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008;8(11):727–33.PubMedCrossRef Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008;8(11):727–33.PubMedCrossRef
go back to reference Boersma C, Broer A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value in Health, 2010:853–6. Boersma C, Broer A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value in Health, 2010:853–6.
go back to reference Brisson M, Velde N van de, Wals P de, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007;25(29):5399–408.PubMedCrossRef Brisson M, Velde N van de, Wals P de, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007;25(29):5399–408.PubMedCrossRef
go back to reference Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005;331(7514):446–8.PubMedCrossRef Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005;331(7514):446–8.PubMedCrossRef
go back to reference Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R et al. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Health Econ 2006;15(1):1–4.PubMed Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R et al. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Health Econ 2006;15(1):1–4.PubMed
go back to reference Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361:1139–51.PubMedCrossRef Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361:1139–51.PubMedCrossRef
go back to reference Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized double-blind non-inferiority trial. Lancet 2007;370:949–56.PubMedCrossRef Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized double-blind non-inferiority trial. Lancet 2007;370:949–56.PubMedCrossRef
go back to reference Ettema HB, Hoppener MR, Büller HR et al. Tromboseprofylaxe in de orthopedische chirurgie: inzichten en onzekerheden. NTvG 2003;147:1842–7. Ettema HB, Hoppener MR, Büller HR et al. Tromboseprofylaxe in de orthopedische chirurgie: inzichten en onzekerheden. NTvG 2003;147:1842–7.
go back to reference Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981–92.PubMedCrossRef Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981–92.PubMedCrossRef
go back to reference Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 2001;10(7):587–99.PubMedCrossRef Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 2001;10(7):587–99.PubMedCrossRef
go back to reference Hoomans T, Roer N van der, Severens JL, Delwel GO. Kosteneffectiviteit van nieuwe geneesmiddelen; van belang bij geneesmiddelenvergoeding maar voor verbetering vatbaar. NTvG 2010;154:A958. Hoomans T, Roer N van der, Severens JL, Delwel GO. Kosteneffectiviteit van nieuwe geneesmiddelen; van belang bij geneesmiddelenvergoeding maar voor verbetering vatbaar. NTvG 2010;154:A958.
go back to reference Keeler EB, Cretin S. Discounting of life-saving and other non-monetary effects. Managment Science 1983;29:300–6.CrossRef Keeler EB, Cretin S. Discounting of life-saving and other non-monetary effects. Managment Science 1983;29:300–6.CrossRef
go back to reference Klok RM, Postma MJ. Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrant. Expert Rev Pharmacon Outcomes Res 2004;4(6):599–601.CrossRef Klok RM, Postma MJ. Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrant. Expert Rev Pharmacon Outcomes Res 2004;4(6):599–601.CrossRef
go back to reference Klok RM, Brouwer WB, Annemans LJ, Bos JM, Postma MJ. Towards a healthier discount procedure. Expert Rev Pharmacoecon Outcomes Res 2005;5(1):59–63.CrossRef Klok RM, Brouwer WB, Annemans LJ, Bos JM, Postma MJ. Towards a healthier discount procedure. Expert Rev Pharmacoecon Outcomes Res 2005;5(1):59–63.CrossRef
go back to reference Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011;365:883–91.PubMedCrossRef Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011;365:883–91.PubMedCrossRef
go back to reference Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analysis. Brit Med J 2011;343:d6333. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analysis. Brit Med J 2011;343:d6333.
go back to reference Postma MJ, Kappelhoff BS, Hulst M van, Brouwers JRBJ. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands. Journal of Medical Economics, 2012. Postma MJ, Kappelhoff BS, Hulst M van, Brouwers JRBJ. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands. Journal of Medical Economics, 2012.
go back to reference Pomp M. Gezond en actief ouder worden: de maatschappelijke baten van healthy aging onderzoek. Rapport i.o.v. het UMCG, december 2011. Pomp M. Gezond en actief ouder worden: de maatschappelijke baten van healthy aging onderzoek. Rapport i.o.v. het UMCG, december 2011.
go back to reference Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009;27(35):4776–83.PubMedCrossRef Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009;27(35):4776–83.PubMedCrossRef
go back to reference Rozenbaum MH, Sanders EAM, Hoek AJ van, Jansen AGSC, Ende A van der, Dobbelsteen G van den, Rodenburg GD, Hak E, Postma MJ. Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. Britt Med J 2010;DOI:10.1136/bmj.c2509. Rozenbaum MH, Sanders EAM, Hoek AJ van, Jansen AGSC, Ende A van der, Dobbelsteen G van den, Rodenburg GD, Hak E, Postma MJ. Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. Britt Med J 2010;DOI:10.1136/bmj.c2509.
Metagegevens
Titel
Farmaco-economie
Auteurs
Maarten Postma
Cornelis Boersma
Copyright
2014
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-0265-9_7